New York State Common Retirement Fund Has $170,000 Stock Position in SI-BONE, Inc. (NASDAQ:SIBN)

New York State Common Retirement Fund lowered its holdings in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 72.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,135 shares of the company's stock after selling 31,676 shares during the period. New York State Common Retirement Fund's holdings in SI-BONE were worth $170,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Impax Asset Management Group plc lifted its stake in SI-BONE by 41.3% in the 3rd quarter. Impax Asset Management Group plc now owns 758,521 shares of the company's stock worth $10,604,000 after acquiring an additional 221,604 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of SI-BONE by 1.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 315,092 shares of the company's stock valued at $4,405,000 after buying an additional 5,966 shares during the period. Champlain Investment Partners LLC grew its holdings in shares of SI-BONE by 14.7% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company's stock valued at $39,145,000 after acquiring an additional 358,821 shares in the last quarter. Millrace Asset Group Inc. purchased a new position in shares of SI-BONE during the 3rd quarter valued at $1,056,000. Finally, FMR LLC increased its stake in shares of SI-BONE by 103.6% in the third quarter. FMR LLC now owns 2,354 shares of the company's stock worth $33,000 after acquiring an additional 1,198 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company's stock.

Remove Ads

SI-BONE Trading Down 1.8 %

NASDAQ:SIBN traded down $0.30 on Friday, hitting $16.06. 464,391 shares of the stock were exchanged, compared to its average volume of 358,948. The stock has a market capitalization of $681.80 million, a price-to-earnings ratio of -17.46 and a beta of 1.17. SI-BONE, Inc. has a 52 week low of $11.70 and a 52 week high of $19.16. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. The company's 50-day moving average price is $16.44 and its 200 day moving average price is $14.89.

SI-BONE (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.05. The firm had revenue of $49.00 million during the quarter, compared to analysts' expectations of $48.87 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. On average, equities research analysts forecast that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

Insider Activity at SI-BONE

In related news, insider Anthony J. Recupero sold 3,670 shares of the company's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $13.90, for a total value of $51,013.00. Following the completion of the sale, the insider now owns 222,814 shares in the company, valued at $3,097,114.60. This represents a 1.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Anshul Maheshwari sold 5,304 shares of the company's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $13.91, for a total transaction of $73,778.64. Following the completion of the sale, the chief financial officer now owns 189,319 shares of the company's stock, valued at approximately $2,633,427.29. This represents a 2.73 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 9,311 shares of company stock worth $130,356. 3.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

SIBN has been the subject of several research reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price objective on shares of SI-BONE in a research report on Tuesday, February 25th. Truist Financial reissued a "buy" rating and issued a $22.00 price objective (up from $18.00) on shares of SI-BONE in a research report on Tuesday, February 25th. Finally, Needham & Company LLC raised their price objective on SI-BONE from $20.00 to $24.00 and gave the stock a "buy" rating in a research report on Tuesday, February 25th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SI-BONE has an average rating of "Buy" and a consensus price target of $24.50.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.